Stock listing

NASDAQ:QNRX Quoin Pharmaceuticals. Ltd Stock

Follow Quoin Pharmaceuticals. Ltd into a list and get an email when it puts out news.

Share price · NASDAQ:QNRX

$3.28 USD -0.28 (-7.9%)

Close on Nov 20, 2026

Past year -82.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$3.18 – $3.54 USDNov 20, 2026
Volume
11,312 sharesNov 20, 2026
Market cap
$15.76M USDAt the close on Nov 20, 2026 · price × 4.80M shares outstanding
52-week range
$3.18 – $23.50 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$3.26M USDMedian day 25,422 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Quoin Pharmaceuticals. Ltd logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:QNRX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$3.28-0.28-7.9%$3.50$3.536$3.1811,312
$3.56+0.20+6.0%$3.48$3.56$3.357,033
$3.36-0.20-5.6%$3.645$3.645$3.258,241
$3.56-0.14-3.8%$3.65$3.73$3.5519,880
$3.70-0.05-1.3%$3.99$3.99$3.5516,032
$3.75-0.01-0.3%$3.82$3.83$3.755,492
$3.76+0.03+0.8%$3.81$3.81$3.734,259
$3.73-0.175-4.5%$3.96$3.96$3.716,245
$3.905+0.255+7.0%$3.74$3.905$3.743,520
$3.65-0.20-5.2%$3.79$4.02$3.4525,422
$3.85-0.17-4.2%$3.75$3.97$3.7510,892
$4.02+0.09+2.3%$3.925$4.03$3.889,550
$3.93-0.09-2.2%$4.11$4.34$3.90120,758
$4.02-0.52-11.5%$4.56$4.62$4.0221,331
$4.54+0.39+9.4%$4.19$4.54$3.8736,600
$4.15+0.04+1.0%$4.13$4.15$4.053,300
$4.11+0.06+1.5%$4.07$4.22$3.9116,700
$4.05+0.04+1.0%$4.13$4.13$4.0451,500
$4.01-0.01-0.2%$3.96$4.21$3.9114,900
$4.02+0.01+0.2%$4.082$4.082$4.022,200
$4.01+0.02+0.5%$3.92$4.08$3.9111,200
$3.99-0.05-1.2%$4.01$4.19$3.997,800
$4.04+0.06+1.5%$4.09$4.135$3.958,100
$3.98+0.08+2.1%$4.03$4.05$3.8815,400
$3.90-0.13-3.2%$4.00$4.11$3.9031,700
$4.03-0.07-1.7%$3.95$4.149$3.9124,100
$4.10-0.05-1.2%$4.11$4.29$3.91159,400
$4.15-0.21-4.8%$4.49$4.56$4.1526,400
$4.36-0.14-3.1%$4.83$5.31$4.3050,600
$4.50-0.05-1.1%$4.32$4.68$4.2542,500
$4.55-0.15-3.2%$4.49$4.70$4.3049,000
$4.70-0.02-0.4%$4.61$4.83$4.5026,200
$4.72+0.165+3.6%$4.48$4.88$4.35103,400
$4.555+0.085+1.9%$4.53$4.74$4.36421,100
$4.47-0.25-5.3%$4.81$4.81$4.4720,300
$4.72+0.16+3.5%$4.685$4.80$4.5017,100
$4.56-0.32-6.6%$4.88$5.09$4.55139,200
$4.88-0.38-7.2%$5.30$5.52$4.8064,200
$5.26-1.17-18.2%$6.40$6.41$5.2670,300
$6.43+0.05+0.8%$6.40$6.69$6.24711,000
$6.38-0.37-5.5%$6.83$7.10$6.1239,400
$6.75-0.26-3.7%$7.07$7.15$6.5139,400
$7.01+0.11+1.6%$6.98$7.161$6.9129,300
$6.90-0.16-2.3%$6.92$7.14$6.7652,100
$7.06+0.05+0.7%$6.85$7.15$6.7015,500
$7.01+0.11+1.6%$6.92$7.22$6.4428,100
$6.90+0.10+1.5%$6.826$6.99$6.7552,100
$6.80-0.08-1.2%$6.89$6.89$6.27339,000
$6.88+0.09+1.3%$6.71$6.95$6.6610,200
$6.79-0.11-1.6%$6.87$6.87$6.6665,700
$6.90-0.07-1.0%$6.84$7.00$6.5831,000
$6.97-0.18-2.5%$7.09$7.10$6.84459,200
$7.15-0.11-1.5%$7.33$7.65$7.05196,000
$7.26-0.61-7.8%$7.64$7.687$7.1078,700
$7.87+1.13+16.8%$6.81$8.00$6.26437,100
$6.74+0.23+3.5%$6.50$6.98$6.40371,100
$6.51+0.29+4.7%$5.90$6.58$5.75275,200
$6.22+0.10+1.6%$5.45$6.55$5.43566,500
$6.12+0.965+18.7%$7.22$8.25$5.9531,017,000
$5.155-0.025-0.5%$5.135$5.18$4.66433,900
$5.18+0.11+2.2%$5.10$5.33$5.109,900
$5.07-0.35-6.5%$5.32$5.415$4.8518,200
$5.42-0.15-2.7%$5.395$6.46$5.32931,300
$5.57+0.58+11.6%$5.29$5.88$5.0272,100
$4.99+0.27+5.7%$4.85$5.225$4.6398,100

Splits

5 splits since 2019 · NASDAQ:QNRX · every price before a split is adjusted for it

DayRatioWhat
1-for-35Consolidation
1-for-12Consolidation
2-for-25Consolidation
1-for-4Consolidation
1-for-5Consolidation
Ticker
NASDAQ:QNRX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Quoin Pharmaceuticals. Ltd news

Quoin Pharmaceuticals. Ltd on 6ix

Sector
Health care
Industry
Biotechnology
News releases
4 in the last 12 months · 4 in all · newest Nov 6, 2026 · oldest 2026
Calls
6 calls with a replay · 6 with a transcript · latest Mar 14, 2024
Decks
5 decks · latest August 2026

Valuation

Price/book 0.6× against a median of 1.7×: 2nd lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$17.43M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
0.6×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
0.68

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Quoin Pharmaceuticals. Ltd · NASDAQ:QNRXUS$15.76M−US$17.43Mn/an/an/a0.6×n/a0.0×0.68
SynCore Biotechnology Co., Ltd. · TPEX:4192US$16.80MUS$12.38Mn/a15.6×n/a2.5×−178.5%0.0×n/a
Initiator Pharma A/S · OMXSTO:INITUS$16.74MUS$15.65Mn/an/an/a13.4×n/a1.1×n/a
Neurotech International Ltd. · ASX:NTIUS$16.63MUS$15.06Mn/an/an/a41.1×n/a0.0×n/a
Akari Therapeutics PLC · NASDAQ:AKTXUS$16.41MUS$10.66Mn/an/an/a0.9×n/a0.0×1.49
Lipocine Inc. · NASDAQ:LPCNUS$16.39M−US$5.07Mn/a−1.4×n/a0.8×−249.2%0.0×1.18
MaaT Pharma · EURONEXT:MAATUS$16.11MUS$23.36Mn/a4.7×n/an/a−686.6%n/an/a
Elicera Therapeutics AB · OMXSTO:ELICUS$16.09MUS$10.40Mn/an/an/a2.9×n/a0.0×n/a
Pasithea Therapeutics Corp. · NASDAQ:KTTAUS$16.00M−US$25.22Mn/an/a−0.1×0.4×n/a0.0×0.97
Atossa Therapeutics, Inc. · NASDAQ:ATOSUS$15.92M−US$4.66Mn/an/an/a0.7×n/a0.0×0.87
Celularity Inc. · NASDAQ:CELUUS$15.02MUS$50.46Mn/a2.7×n/an/a−117.3%n/a1.47
Median of the othersUS$16.25MUS$11.52M3.7×−0.1×1.7×−213.8%0.0×1.18

Forecasts

6 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
20.38 USD · Analysts' mean
EPS, year to Dec 2026
-5.25 · 1 analyst

Team and board

Officers

OfficerRole
Michael MyersCo-Founder, Chairman, Chief Executive Officer and Director
Sally LawlorChief Financial Officer
Denise CarterCo-Founder, Chief Operating Officer and Director

Board

DirectorRole
Michael MyersCo-Founder, Chairman, Chief Executive Officer and Director
Denise CarterCo-Founder, Chief Operating Officer and Director
Dennis H. LangerDirector
James CulverwellDirector
Joseph CooperDirector
Michael SemberDirector
Natalie LeongDirector

Events

Results days

QuarterResultsShare move
Q3 2026Nov 5, 2026 · After close−5.2%
Q2 2026Aug 14, 2026 · Before open−15.9%
Q4 2025Mar 26, 2026 · Before open−18.4%
Q3 2025Nov 6, 2025 · Before open−11.2%
Q2 2025Aug 7, 2025 · After close+3.5%
Q1 2025May 13, 2025 · After close+20.3%
Q4 2024Mar 11, 2025 · Before open+2.0%
Q3 2024Nov 8, 2024 · Before open−3.3%
Q2 2024Aug 8, 2024 · After close−5.3%
Q1 2024May 9, 2024 · After close−2.8%
All 20 quarters
QuarterResultsShare move
Q4 2023Mar 13, 2024 · After close−13.8%
Q3 2023Nov 9, 2023 · After close−4.7%
Q2 2023Aug 3, 2023 · After close−10.2%
Q1 2023May 9, 2023 · After close−1.0%
Q4 2022Mar 8, 2023 · After close−7.8%
Q3 2022Nov 10, 2022 · After close−1.0%
Q2 2022Aug 18, 2022 · After close−5.9%
Q1 2022Apr 14, 2022 · Before open−0.8%
Q4 2021Mar 21, 2022+2.0%
Quarter to Sep 30, 2021Dec 20, 2021 · Before open−13.6%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (August 2026)Investor deck26 slidesAugust 2026
Cellect Biotechnology — Investor Presentation (April 2019)Investor deck21 slidesApr 30, 2019
Cellect Biotechnology — Investor Presentation (November 2017)Investor deck22 slidesNov 2, 2017
Cellect Biotechnology — Investor Presentation (March 2017)Investor deck19 slidesMar 23, 2017
Cellect Biotechnology — IPO Roadshow (July 2016)IPO roadshow28 slidesJul 25, 2016

Open Decks

IPO

Went public as Cellect Biotechnology Ltd. Priced at US$6.50 an ADS on Jul 29, 2016.

Price
US$6.50 an ADS
ADSs offered
1,292,308 American depositary shares
Offering size
US$8.4 million
Underwriters
Rodman & Renshaw, Joseph Gunnar & Co., LLC · In the order on the cover
ADSs delivered
On or about Aug 3, 2016

Steps

StepWhen
Draft sent to the SEC in confidenceApr 8, 2016
Filed publiclyJul 7, 2016
Amended 5 timesNewest Jul 28, 2016
Shares registered with an exchangeJul 27, 2016
Declared effective by the SECJul 28, 2016
Final prospectus, with the priceAug 1, 2016

Open IPO · From the cover of the final prospectus (424B4) filed Aug 1, 2016

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0000000-280.0K-280.0K
Cost of revenue100.8K100.5K103.4K103.6K104.1K104.8K227.1K125.7K104.2K89.1K
Gross profit-100.8K-100.5K-103.4K-103.6K-104.1K-104.8K-227.1K-280.0K-104.2K-280.0K
Research and development9.80M3.60M3.31M2.67M1.56M244.2K45.6K8.26M5.89M8.26M
Selling, general and administrative6.49M5.93M6.07M6.58M4.50M1.43M1.51M7.97M4.20M7.97M
Operating income-16.3M-9.53M-9.38M-9.26M-6.06M-1.67M-1.56M15.3M10.2M15.3M
Depreciation and amortization100.0K100.0K103.7K104.0K104.0K104.0K227.1K125.7K104.2K89.1K
EBITDA-16.2M-9.43M-9.27M-9.15M-5.96M-1.57M-1.33M15.4M10.3M15.4M
Interest expense0714.1K1.09M47.0K412.3K
Income before tax-15.8M-8.96M-8.69M-9.38M-21.5M-2.10M-1.56M15.3M10.2M15.3M
Income tax-8.95B22.4K-104.0K-12.9M-331.3K1.55M-161.1K-1.17M147.9K
Net income-15.8M-8.96M-8.69M-9.38M-21.5M-2.10M-1.56M15.3M10.2M15.3M
Earnings per share, basic-0.30-1.00-8.80-23.23-0.01-0.70-0.52
Earnings per share, diluted-0.01-0.70-0.52

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents3.82M3.62M2.40M2.86M7.48M323.8K5.24M4.77M3.96M1.63M
Short-term investments14.9M10.4M8.29M9.99M04.03M6.41M
Receivables77.3K57.8K70.6K172.0K
Current assets20.0M14.9M11.3M13.4M8.20M465.2K5.38M4.98M8.22M8.42M
Total assets20.4M15.7M12.2M14.5M9.36M1.38M6.17M5.52M8.75M8.81M
Accounts payable1.26M905.7K526.5K605.6K923.2K45.7K237.4K490.5K349.0K
Current liabilities5.55M4.18M3.58M3.53M4.58M7.99M1.05M1.31M1.18M905.5K
Total debt1.21M310.7K15.1K
Total liabilities7.27M6.50M6.51M7.05M8.70M7.99M1.88M1.80M3.32M1.41M
Shareholders' equity13.1M9.20M5.66M7.41M657.0K-6.61M-4.51M3.73M5.43M7.40M
Shares outstanding52.4M8.95M987.2K403.9K3.35B1.20B3.35B625343

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-13.5M-7.86M-7.86M-8.48M-5.72M-1.34M-1.30M-6.57M-4.98M-3.77M
Capital spending-40-4-250.0K-625.0K-125.0K-34.5K-182.5K-74.5K-330.6K
Free cash flow-13.5M-7.86M-7.86M-8.73M-6.35M-1.46M-5.74M-6.76M-5.05M-4.10M
Cash from investing-4.28M-1.89M2.19M-10.1M-625.0K-125.0K-30.3K3.81M2.83M-4.71M
Cash from financing18.0M11.0M5.22M14.0M13.5M1.79M1.30M3.55M4.43M9.13M
Dividends paid-65.3M
Share buybacks-14.8M
Change in cash194.8K1.22M-459.4K-4.62M7.16M323.8K-40809.8K2.32M653.5K

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
8-K · Current reportNov 12, 2026Meeting outcomeSEC
8-K · Current reportNov 6, 2026ResultsSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
EFFECT · Notice that a registration is effectiveNov 5, 2026Other filingsSEC
8-K · Current reportNov 4, 2026Material contractSEC
424B5 · ProspectusNov 4, 2026Offer documentSEC
424B5 · ProspectusNov 4, 2026Offer documentSEC
S-3 · Registration statementOct 27, 2026Offer documentSEC
Show 200 filings
FilingDateTypeFiled with
4/A · Change in ownership, amendedOct 26, 2026Insider tradeSEC
8-K · Current reportOct 20, 2026Current reportSEC
8-K · Current reportOct 14, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 7, 2026Big-stake noticeSEC
DEF 14A · Proxy statementOct 2, 2026Meeting noticeSEC
EFFECT · Notice that a registration is effectiveSep 28, 2026Other filingsSEC
424B3 · ProspectusSep 25, 2026Offer documentSEC
PRE 14A · Preliminary proxy statementSep 22, 2026Meeting noticeSEC
8-K · Current reportSep 22, 2026Current reportSEC
S-3 · Registration statementSep 18, 2026Offer documentSEC
DSep 10, 2026Other filingsSEC
8-K · Current reportSep 10, 2026Current reportSEC
4 · Change in ownershipSep 1, 2026Insider tradeSEC
4 · Change in ownershipSep 1, 2026Insider tradeSEC
4 · Change in ownershipSep 1, 2026Insider tradeSEC
4 · Change in ownershipSep 1, 2026Insider tradeSEC
4 · Change in ownershipAug 28, 2026Insider tradeSEC
4 · Change in ownershipAug 28, 2026Insider tradeSEC
8-K · Current reportAug 28, 2026Material contractSEC
8-K · Current reportAug 20, 2026Management or board changeSEC
8-K · Current reportAug 14, 2026ResultsSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
ARS · Annual report to shareholdersJul 16, 2026Annual reportSEC
DEF 14A · Proxy statementJul 16, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementJul 6, 2026Meeting noticeSEC
8-K · Current reportJun 23, 2026Current reportSEC
8-K · Current reportJun 4, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeJun 2, 2026Big-stake noticeSEC
424B3 · ProspectusJun 2, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
8-K · Current reportMay 7, 2026ResultsSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 29, 2026Big-stake noticeSEC
4 · Change in ownershipMar 31, 2026Insider tradeSEC
10-K · Annual reportMar 26, 2026Annual reportSEC
8-K · Current reportMar 26, 2026ResultsSEC
8-K · Current reportMar 11, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 11, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 6, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 2, 2026Big-stake noticeSEC
3 · Initial statement of ownershipFeb 2, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJan 28, 2026Big-stake noticeSEC
8-K · Current reportJan 20, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeDec 16, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeDec 15, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeDec 11, 2025Big-stake noticeSEC
424B3 · ProspectusDec 5, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveDec 5, 2025Other filingsSEC
4 · Change in ownershipDec 3, 2025Insider tradeSEC
CORRESP · Letter to the SECDec 2, 2025Other filingsSEC
8-K · Current reportNov 17, 2025Management or board changeSEC
8-K · Current reportNov 12, 2025Current reportSEC
S-3 · Registration statementNov 7, 2025Offer documentSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeOct 27, 2025Big-stake noticeSEC
DOct 23, 2025Other filingsSEC
8-K · Current reportOct 21, 2025Current reportSEC
4 · Change in ownershipOct 15, 2025Insider tradeSEC
8-K · Current reportOct 15, 2025Material contractSEC
3 · Initial statement of ownershipSep 8, 2025Insider tradeSEC
S-8 · Registration statement for employee plansAug 27, 2025Offer documentSEC
8-K · Current reportAug 27, 2025Management or board changeSEC
S-8 · Registration statement for employee plansAug 26, 2025Offer documentSEC
4 · Change in ownershipAug 25, 2025Insider tradeSEC
4 · Change in ownershipAug 25, 2025Insider tradeSEC
4 · Change in ownershipAug 25, 2025Insider tradeSEC
8-K · Current reportAug 21, 2025Management or board changeSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
ARS · Annual report to shareholdersJul 17, 2025Annual reportSEC
DEF 14A · Proxy statementJul 17, 2025Meeting noticeSEC
8-K · Current reportJul 8, 2025Management or board changeSEC
PRE 14A · Preliminary proxy statementJul 7, 2025Meeting noticeSEC
8-K · Current reportJun 25, 2025Current reportSEC
8-K · Current reportJun 20, 2025Current reportSEC
4/A · Change in ownership, amendedJun 13, 2025Insider tradeSEC
4/A · Change in ownership, amendedJun 13, 2025Insider tradeSEC
8-K · Current reportJun 4, 2025Management or board changeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
8-K · Current reportMay 22, 2025Current reportSEC
8-K · Current reportMay 21, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
8-K · Current reportMay 14, 2025ResultsSEC
10-Q · Quarterly reportMay 13, 2025Quarterly reportSEC
8-K · Current reportApr 30, 2025Current reportSEC
8-K · Current reportApr 4, 2025Current reportSEC
8-K · Current reportApr 4, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveApr 4, 2025Other filingsSEC
8-K · Current reportApr 2, 2025Current reportSEC
POS AM · Amendment to an effective registrationMar 28, 2025Offer documentSEC
8-K · Current reportMar 20, 2025Current reportSEC
10-K · Annual reportMar 13, 2025Annual reportSEC
8-K · Current reportMar 13, 2025ResultsSEC
8-K · Current reportFeb 27, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
8-K · Current reportFeb 4, 2025Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 28, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJan 28, 2025Big-stake noticeSEC
8-K · Current reportJan 23, 2025Current reportSEC
8-K · Current reportJan 16, 2025Current reportSEC
8-K · Current reportJan 6, 2025Current reportSEC
SCHEDULE 13D · Big-stake noticeJan 2, 2025Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeJan 2, 2025Big-stake noticeSEC
4 · Change in ownershipDec 27, 2024Insider tradeSEC
4 · Change in ownershipDec 27, 2024Insider tradeSEC
4 · Change in ownershipDec 27, 2024Insider tradeSEC
4 · Change in ownershipDec 27, 2024Insider tradeSEC
8-K · Current reportDec 26, 2024Material contractSEC
424B4 · ProspectusDec 23, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveDec 23, 2024Other filingsSEC
8-K · Current reportDec 19, 2024Current reportSEC
S-1/A · Registration statement, amendedDec 18, 2024Offer documentSEC
CORRESP · Letter to the SECDec 17, 2024Other filingsSEC
UPLOAD · Letter from the SECDec 17, 2024Other filingsSEC
S-1 · Registration statementDec 11, 2024Offer documentSEC
424B3 · ProspectusDec 11, 2024Offer documentSEC
4 · Change in ownershipDec 10, 2024Insider tradeSEC
4 · Change in ownershipDec 10, 2024Insider tradeSEC
4 · Change in ownershipDec 10, 2024Insider tradeSEC
4 · Change in ownershipDec 10, 2024Insider tradeSEC
4 · Change in ownershipDec 10, 2024Insider tradeSEC
4 · Change in ownershipDec 10, 2024Insider tradeSEC
4 · Change in ownershipDec 10, 2024Insider tradeSEC
4 · Change in ownershipDec 10, 2024Insider tradeSEC
8-K · Current reportDec 10, 2024Management or board changeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
424B3 · ProspectusNov 8, 2024Offer documentSEC
8-K · Current reportNov 8, 2024ResultsSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportOct 31, 2024Current reportSEC
DEF 14A · Proxy statementOct 24, 2024Meeting noticeSEC
ARS · Annual report to shareholdersOct 24, 2024Annual reportSEC
PRE 14A · Preliminary proxy statementOct 11, 2024Meeting noticeSEC
8-K · Current reportSep 30, 2024Current reportSEC
4 · Change in ownershipSep 11, 2024Insider tradeSEC
4 · Change in ownershipSep 5, 2024Insider tradeSEC
4 · Change in ownershipSep 5, 2024Insider tradeSEC
8-K · Current reportAug 13, 2024ResultsSEC
424B3 · ProspectusAug 12, 2024Offer documentSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
144 · Notice of proposed saleJun 7, 2024Other filingsSEC
424B3 · ProspectusMay 10, 2024Offer documentSEC
10-Q · Quarterly reportMay 9, 2024Quarterly reportSEC
424B3 · ProspectusMay 8, 2024Offer documentSEC
8-K · Current reportMay 3, 2024Current reportSEC
8-K · Current reportApr 9, 2024Meeting outcomeSEC
EFFECT · Notice that a registration is effectiveApr 4, 2024Other filingsSEC
DEFA14A · Additional proxy materialApr 2, 2024Meeting noticeSEC
POS AM · Amendment to an effective registrationMar 29, 2024Offer documentSEC
10-K · Annual reportMar 14, 2024Annual reportSEC
8-K · Current reportMar 13, 2024ResultsSEC
424B3 · ProspectusMar 8, 2024Offer documentSEC
424B3 · ProspectusMar 8, 2024Offer documentSEC
8-K · Current reportMar 8, 2024Material contractSEC
424B4 · ProspectusMar 6, 2024Offer documentSEC
8-K · Current reportMar 6, 2024Current reportSEC
424B3 · ProspectusMar 4, 2024Offer documentSEC
DEF 14A · Proxy statementFeb 27, 2024Meeting noticeSEC
EFFECT · Notice that a registration is effectiveFeb 15, 2024Other filingsSEC
CORRESP · Letter to the SECFeb 14, 2024Other filingsSEC
CORRESP · Letter to the SECFeb 14, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
UPLOAD · Letter from the SECFeb 13, 2024Other filingsSEC
S-1/A · Registration statement, amendedFeb 13, 2024Offer documentSEC
PRE 14A · Preliminary proxy statementFeb 13, 2024Meeting noticeSEC
S-1 · Registration statementFeb 12, 2024Offer documentSEC
424B3 · ProspectusJan 30, 2024Offer documentSEC
8-K · Current reportJan 30, 2024Material contractSEC
424B3 · ProspectusDec 18, 2023Offer documentSEC
8-K · Current reportDec 18, 2023Current reportSEC

This page holds 200 of 587 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Quoin Pharmaceuticals. Ltd’s releases

Common shares
4,804,161
Fully diluted
4,804,161

Fully diluted

LineShares
Common shares4,804,161

Share count over time

CountShares
Nov 22, 20264,804,161

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Stonepine Capital Management, LLC252K0.36%US$1.15MSep 30, 2026
Nantahala Capital Management, LLC236K0.34%US$1.08MSep 30, 2026
Stempoint Capital LP236K0.34%US$1.08MSep 30, 2026
Sphera Funds Management LTD.236K0.34%US$1.08MSep 30, 2026
AIGH Capital Management LLC236K0.34%US$1.08MSep 30, 2026
Millennium236K0.34%US$1.05MSep 30, 2026
Ikarian Capital, LLC212K0.30%US$965KSep 30, 2026
Empery Asset Management, LP205K0.29%US$934KSep 30, 2026
Dauntless Investment Group, LLC194K0.28%US$884KSep 30, 2026
J. Goldman & Co LP190K0.27%US$867KSep 30, 2026
All 24 holders
HolderSharesOf the companyValueAs of
Diadema Partners LP146K0.21%US$668KSep 30, 2026
DAFNA Capital Management LLC132K0.19%US$603KSep 30, 2026
Boothbay Fund Management, LLC59,8380.09%US$273KSep 30, 2026
Nano Cap New Millennium Growth Fund L P50,0000.07%US$228KSep 30, 2026
Citadel20,3070.03%US$92,600Sep 30, 2026
Jane Street19,4560.03%US$88,719Sep 30, 2026
Morgan Stanley8,0000.01%US$36,480Sep 30, 2026
Rhumbline Advisers3,169<0.01%US$14,445Sep 30, 2026
Nuveen437<0.01%US$2,133Sep 30, 2026
Arax Advisory Partners171<0.01%US$780Sep 30, 2026
Tower Research Capital LLC (TRC)136<0.01%US$620Sep 30, 2026
SBI Securities Co., Ltd.128<0.01%US$584Sep 30, 2026
Caitong International Asset Management Co., Ltd9<0.01%US$41Sep 30, 2026
Nisa Investment Advisors, LLC4<0.01%US$18Sep 30, 2026

Big stakes

StakeStakeSharesDateFiling
Stempoint Capital LP9.90%507KSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Dennis Langer
Other companies: Ernexa Therapeutics Inc. (Director · May 1, 2021 – Dec 8, 2021 · Past); Pernix Therapeutics Holdings Inc (Director · Nov 4, 2016 – May 22, 2018 · Past); Delcath Systems, Inc. (Director · Dec 11, 2014 – Jun 10, 2015 · Past); Dicerna Pharmaceuticals Inc (Director · Sep 24, 2013 – Jun 20, 2019 · Past); Myrexis Inc (Director · Dec 8, 2011 – Dec 8, 2011 · Past); Myriad Genetics, Inc. (Director · Dec 2, 2011 – Jun 30, 2022 · Past)
Director · Since at least Jan 1, 2023
Joseph Cooper
Other companies: Bioenvision Inc (Director · Oct 6, 2006 – Jan 3, 2007 · Past); Medicis Pharmaceutical Corp (EVP,Corp & Product Development · Jul 10, 2006 – Apr 4, 2010 · Past)
Director · Since at least Jan 1, 2023
Michael Sember
Other companies: Iomed Inc (Director · Nov 9, 2006 – Aug 9, 2007 · Past); Soligenix, Inc. (Chief Executive Officer, Director · Apr 10, 2006 – Apr 10, 2006 · Past)
Director · Since at least Jan 1, 2023
Anthony James CulverwellDirector · Since at least Jan 1, 2023
Denise CarterCo-Founder, Chief Operating Officer and Director · Since at least Jan 1, 2023
Gordon DunnChief Financial Officer · Jan 1, 2023 – Dec 23, 2024 · Past
James CulverwellDirector · Since at least Nov 4, 2026
Michael MyersCo-Founder, Chairman, Chief Executive Officer and Director · Since at least Jan 1, 2023
Natalie LeongDirector · Since at least Nov 4, 2026
Sally LawlorChief Financial Officer · Since at least Aug 18, 2025

Open People

Log in to ask 6ix AI your own questions about Quoin Pharmaceuticals. Ltd.